Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Financial Markets Research: Palatin Technologies' Bremelanotide - Competition And Regulatory Risk Cloud Potential

Published by: Datamonitor

Published: Jul. 31, 2006 - 15 Pages


Table of Contents


SUMMARY
Competition and regulatory risk cloud potential for PTN's Bremelanotide


PALATIN TECHNOLOGIES
Overview
Bremelanotide (PT-141)


ERECTILE DYSFUNCTION
Overview
Despite widely popular options, unmet need still exists
Novel melanocortin agonist shows promise in the treatment of ED
Potential in female sexual dysfunction could be an important differentiating factor


FACTORS AFFECTING THE POTENTIAL FOR BREMELANOTIDE
Stiff competition and unclear efficacy diminish bremelanotide's potential in ED
High placebo-effect that has plagued historical ED trials could slow path to market
Use in combination with PDE-5 inhibitors viewed as intriguing
Unclear benchmarks could slow development for female sexual dysfunction


DATAMONITOR BREMELANOTIDE FORECAST
Despite growing market, annual cost of therapy estimates appear overstated
Bremelanotide could find niche in patients who do not respond to PDE-5 inhibitors
Slow development road raises questions about bremelanotide's potential
Off-label use in female sexual dysfunction patients could boost revenues


APPENDIX
Supplementary data
Datamonitor Healthcare
Disclosure information
Ask the analyst


List of Tables
Table 1: Estimated US bremelanotide revenues 2009-2013
Table 2: US erectile dysfunction model

Abstract

Introduction

Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Scope
  • Explores the regulatory and commercial potential for PTN's bremelanotide, a novel agent in development for male and female sexual dysfunction
  • Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction
Highlights

While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN's bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.

Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.

Reasons to Purchase
  • Understand the commercial potential for Palatin Technologies' Bremelanotide through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008